Linklaters advised Qatar Investment Authority (QIA) on its investment in Oricell Therapeutics Company Limited (Oricell), a China-based innovative biopharmaceutical company focussing on the development of novel immunotherapeutics. Oricell has raised US$45m in this Series B-1 financing round led by QIA and RTW Investments. The new injection of capital will be utilised primarily to support the company’s […]
The post Linklaters advises QIA on its investment in China-based biopharmaceutical company Oricell Therapeutics appeared first on Legal Desire.